In The UK Why Do We Have 140 licensed Dermal Fillers Whereas there are only 25 in the USA ?

140 Fillers or 25? What the Difference Between CE Marking and FDA Approval Actually Means for Patients and Practitioners

The European market has over 140 CE-marked dermal fillers. The United States has fewer than 25 FDA-approved products. That disparity is not a coincidence — and understanding why it exists has genuine clinical implications.

Over 140 dermal fillers are currently licensed and CE-marked for use in the European market. The United States, by contrast, has fewer than 25 products approved by the FDA. The same fundamental product category, injectable hyaluronic acid or calcium hydroxylapatite for facial enhancement, regulated to dramatically different degrees of evidential rigour in two of the world's most sophisticated regulatory jurisdictions.

The disparity is not a reflection of greater European innovation or a more diverse range of genuinely distinct clinical products. It is a reflection of fundamentally different regulatory philosophies, and understanding those philosophies is one of the most clinically important things a practitioner working in the UK aesthetic medicine market can do.

The CE mark (Conformité Européenne) is a designation that indicates a product complies Nefertiti Neck Lift with Botox European Union safety, health, and environmental protection requirements. For medical devices, including dermal fillers, CE marking under the EU Medical Device Regulation (MDR 2017/745) means that the product has been assessed for safety and performance, that the manufacturer meets MDR standards, and that the product is registered in the European Database on Medical Devices (EUDAMED) with a Unique Device Identifier.

What CE marking does not require, or has not historically required in the way that FDA approval does, is a comprehensive demonstration of clinical efficacy through independently reviewed, prospectively conducted clinical trials. The conformity assessment process has traditionally been conducted by third-party "notified bodies" rather than by a government regulatory agency with the power and resources of the FDA, and the bar for demonstrating that a product performs as intended has been lower than the bar for FDA approval.

It is worth acknowledging that the European regulatory landscape has tightened considerably in recent years. The new MDR 2017/745, which replaced the earlier Medical Device Directive, has introduced more stringent requirements for clinical evidence, post-market surveillance, and transparency. Dermal fillers are now classified under Annex XVI as products without an intended medical purpose but with significant safety implications, subject to Common Specifications that require clinical evaluation data. The direction of travel is towards greater rigour. The legacy of the old regime, a large number of products that entered the market under a less demanding framework, persists in the number of CE-marked products currently available.

The FDA classifies most dermal fillers as Class III medical devices — the highest risk classification, shared with pacemakers and implantable defibrillators. This classification carries the most demanding approval pathway: Pre-Market Approval (PMA), which requires the manufacturer to submit comprehensive clinical trial data demonstrating both the safety and the efficacy of the product for each specific intended use. Clinical trials intended to support the approval of a dermal filler product are reviewed and approved by the FDA prior to study initiation through the Investigational Device Exemption process. The FDA approves dermal fillers for specific, defined anatomic locations and approval for one area does not automatically extend to another.

The FDA's requirement for indication-specific approval is worth particular attention. A product approved for nasolabial folds requires separate clinical trial evidence before it can be approved for lip augmentation. A product approved for the face requires separate evidence before it can be used on the hands. This granular, indication-level evidential requirement has no direct equivalent in the CE marking process, and it means that the clinical evidence supporting an FDA-approved product is both more extensive and more specifically applicable to the clinical situation in which it is used.

The disparity in the number of available products is not primarily a reflection of the diversity of clinical need. Hyaluronic acid fillers, across their many branded variations, share the same fundamental mechanism of action. The meaningful clinical distinctions between products, molecular weight, degree of crosslinking, concentration, rheological properties, represent a relatively small number of genuinely distinct product types. The 140 CE-marked products in Europe include a great many variations on established formulations that have entered the market with limited independent clinical evidence distinguishing their performance from existing approved products.

This is not a trivial observation. A practitioner choosing between products in the European market cannot assume that CE marking confers equivalence with FDA approval. The evidential basis for CE-marked products varies enormously, from products with extensive, independently conducted clinical trial data, to products whose CE marking rests primarily on demonstration of manufacturing compliance and biocompatibility testing.

The practitioner who assumes that any CE-marked filler is as thoroughly evaluated as an FDA-approved one is making an assumption that the regulatory frameworks do not support.

The practical consequence of this regulatory disparity is that the burden of product evaluation falls more heavily on the practitioner in the European market than in the American one.

An American practitioner choosing between FDA-approved fillers can be confident that each product has cleared a meaningful evidential bar. A European practitioner choosing between CE-marked products is operating in a market where that confidence is not uniformly warranted and where the responsibility to evaluate the evidence behind individual products, rather than simply accepting regulatory approval as a proxy for clinical validation, is correspondingly greater.

This connects directly to the evidence problem we examined in an earlier piece in this series. The same critical reading skills that distinguish credible clinical evidence from promotional material apply with particular force to the evaluation of filler products, examining who funded the studies, what the study designs were, whether the evidence is indication-specific, and whether independent replication exists.

A filler that is CE-marked and manufactured to GMP standards by a reputable company may still have a thinner clinical evidence base than its regulatory status implies.

The FDA's granular, indication-level approach to approval has a safety dimension that is directly relevant to the vascular occlusion risks we have discussed elsewhere in this blog. The FDA has incorporated additional measures into its regulatory strategy for fillers used around the eyes, nose, and glabella — high-risk anatomical areas — requiring clinical trials to actively and deliberately monitor for visual impairment and to have measures in place to quickly treat subjects if vascular compromise occurs. This level of indication-specific safety scrutiny is not a standard feature of CE marking for the same products.

The FDA's adverse event reporting database for dermal fillers, the MDR database, is also a valuable resource that has no direct European equivalent of equivalent scope and accessibility.

FDA adverse event reports for dermal fillers have steadily increased, with 1,478 reports received in 2023, with vascular system impairment continuing to be a common serious adverse event. The systematic collection and publication of this data allows practitioners, researchers, and patients to understand the real-world safety profile of approved products in a way that is considerably harder to achieve in the European regulatory environment.

It would be misleading to suggest that the European regulatory framework is static or indifferent to these concerns. The new MDR, fully implemented from 2021, represents a meaningful tightening of requirements, and the Annex XVI Common Specifications for aesthetic injectables introduced specific clinical evidence obligations that did not exist under the old Directive. The requirement for post-market clinical follow-up and the obligation to register products in EUDAMED represent genuine improvements in transparency and accountability.

The question is not whether Europe is moving in the right direction; it is. The question is whether the legacy of a less demanding framework, and the 140-plus products that entered the market under it, is being addressed with sufficient rigour and speed.

The answer, for the practitioner trying to make evidence-based product choices today, is that the regulatory label alone is an insufficient guide and that the habit of reading the small print, examining the evidence, and asking who funded the studies, is as necessary when choosing a filler as it is when evaluating any other clinical intervention.

The difference between 140 CE-marked products and 25 FDA-approved ones is a difference in regulatory philosophy; in how much clinical evidence is required before a product reaches the market, and how specifically that evidence must be tied to the indications for which the product will be used. That difference has practical implications for practitioners, for patients, and for the honest evaluation of clinical evidence in aesthetic medicine.

A CE mark is a meaningful regulatory designation. It is not the same as FDA approval. Knowing the difference and applying the clinical scepticism that difference warrants is part of what it means to practise evidence-based aesthetic medicine in the European market.

The views expressed in Clinical Perspectives are the author's own and reflect their personal and professional experience in aesthetic medicine.

References

EU MDR 2017/745 Annex XVI and Common Specifications (EU) 2022/2346 for aesthetic injectables. European Commission.-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745

FDA Executive Summary: General Issues Panel Meeting on Dermal Fillers. U.S. Food and Drug Administration.2021. /media/146870/download

FDA Executive Summary: General Issues Panel Meeting on Dermal Fillers. U.S. Food and Drug Administration.2024. /media/188185/download

Regulatory Map for Injectable Dermal Fillers: US, EU, China, South Korea, Brazil. Hafiller. 2026. /news/blog/2026-regulatory-map-for-injectable-dermal-fillers-us-eu-china-south-korea-brazil/

CE Marked vs FDA Approved Aesthetic Products. e-Fillers. 2025. https://e-fillers.com/blog/ce-marked-vs-fda-approved-aesthetic-products

What a Toxin Scientist Taught Us About Botulinum Toxin

How Can Anti-wrinkle Injections Be The Safest Treatment in Aesthetic Medicine - And Yet Paradoxically the Most Dangerous ?

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Doctors
Company Ltd
Company no.